# BigHat Biosciences

Source: https://onco.cc/companies/bighat-biosciences/  
OnCo record `bighat-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BigHat uses machine learning and a fast automated lab to design antibodies. Its first cancer drug, an antibody carrying a chemotherapy payload to stomach and bowel tumours, entered human trials in 2026.

## Summary

BigHat Biosciences, based in San Mateo, California, is an AI-native antibody company. Its Milliner platform pairs a synthetic biology wet lab that can synthesise, purify and characterise hundreds of antibodies a week with machine learning that proposes the next designs. Lead programme BHB810 is a CDH17-directed VHH-Fc antibody-drug conjugate with a compact antibody format and a stable payload; across about 30 patient- and cell-derived tumour models it produced complete or near-complete tumour clearance, and the first patient was dosed in a phase 1 dose-escalation trial in gastric, gastro-oesophageal junction and other advanced gastrointestinal tumours on 1 September 2026. BigHat has completed collaborations with Merck and Johnson and Johnson and partners with Eli Lilly through Lilly TuneLab. The company describes itself as a Series B company that has raised more than USD 100 million; round details were not on fetched pages.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: San Mateo, CA
- Type: biotech
- Website: https://www.bighatbio.com

## Notes

- Colorectal included because the trial covers advanced gastrointestinal tumours broadly; specific enrolment beyond gastric and GEJ not confirmed. Founding year and round amounts not sourced.

## Sources

- Official website: https://www.bighatbio.com
- First patient dosed with BHB810 (September 2026): https://bighatbio.com/news/bighat-biosciences-announces-first-patient-dosed-in-phase-1-trial-evaluating-bhb810
- News: https://bighatbio.com/news

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- trials: [Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma](https://onco.cc/trials/nct07529808/)

---
JSON: https://onco.cc/api/v1/entities/bighat-biosciences.json